WHAT IS CLAIMED IS:

1. A compound of formula (I):



(I)

or a stereoisomeric form or mixture of stereoisomeric forms or a pharmaceutically acceptable salt form thereof, wherein

B is selected from phenyl substituted with 1-3 X, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 1-3 X;

R^1 , at each occurrence, is individually selected from F, Cl, Br, I, CN, and C_{1-4} alkyl, C_{1-3} alkoxy ;

n is selected from 1, 2, 3 and 4;

X is selected from CN, F, Cl, Br, and I;

Y is selected from $-CH_2-$, -NH-, and -O-; and

Z is selected from F, Cl, Br, CN, and C_{1-4} alkyl.

2. A compound of claim 1, wherein the compound is of formula (I-i):



(I-i)

or a stereoisomeric form or mixture of stereoisomeric forms or a pharmaceutically acceptable salt form thereof, wherein

R^1 , at each occurrence, is individually selected from F, Cl, Br, I, CN, and C_{1-4} alkyl, C_{1-3} alkoxy ;

n is selected from 1, 2, 3 and 4;

X is selected from CN, F, Cl, Br, and I;

Y is selected from $-CH_2-$, -NH-, and -O-; and

Z is selected from F, Cl, Br, CN, and C_{1-4} alkyl.

3. The compound of claim 1, wherein the compound is of formula (I-ii)



(I-ii).

4. The compound of claim 1, wherein

R^1, at each occurrence, is individually selected from CN, F, Cl, Br, methyl, ethyl, and propyl, i-propyl, methoxy, ethoxy, propoxy, i-propxoy.

5. The compound of claim 1, wherein

X is selected from F, Cl, Br, and CN.

6. The compound of claim 1, wherein

Z is selected from Z is selected from Cl, Br, CN, methyl, ethyl and propyl.

7. The compound of claim 1, wherein

Y is $-CH_2-$.

8. The compound of claim 1, wherein

Y is -NH-.

9. The compound of claim 1, wherein

Y is -O-.

10. The compound of claim 1, wherein

B is selected from phenyl substituted with 1-3 X, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 1-3 X, wherein the heterocyclic system is selected from pyridine, pyrimidine, and thiazole.

11. The compound of claim 2, wherein

X is selected from F, Cl, Br, and CN.

12. The compound of claim 2, wherein

Z is selected from Z is selected from Cl, Br, CN, methyl, ethyl and propyl.

13. The compound of claim 2, wherein

Y is $-CH_2-$.

14. The compound of claim 2, wherein

Y is -NH-.

15. The compound of claim 2, wherein

Y is -O-.

16. The compound of claim 2, wherein

B is selected from phenyl substituted with 1-3 X, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 1-3 X, wherein the heterocyclic system is selected from pyridine, pyrimidine, and thiazole.

17. The compound of claim 1, wherein the compound is selected from:

5-bromo-2-(4-chloroanilino)-4-(2,4,6-trimethylphenoxy)pyridine-N-oxide;

5-bromo-2-(4-chloroanilino)-4-(2,4,6-trimethylanilino)pyridine-N-oxide;

6-[5-Bromo-4-(4-cyano-2,6-dimethyl-phenoxy)-1-oxy-pyridin-2-ylamino]-nicotinonitrile;

[5-Bromo-4-(4-bromo-2,6-dimethyl-phenoxy)-1-oxy-pyridin-2-yl]-(5-bromo-pyridin-2-yl)-amine; and

[5-Bromo-4-(4-Cyano-2,6-dimethyl-phenoxy)-1-oxy-pyridin-2-yl]-(4-cyano-phenyl)-amine.

18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to one of Claim 1 or pharmaceutically acceptable salt form thereof.

19. A method for treating HIV infection which comprises administering to a host in need of such treatment a therapeutically effective amount of a

compound according to one of Claim 1 or pharmaceutically acceptable salt form thereof.

20. A method of treating HIV infection which comprises administering, in combination, to a host in need thereof a therapeutically effective amount of:

(a) a compound according to one of Claim 1; and,

(b) at least one compound selected from the group consisting of HIV reverse transcriptase inhibitors, HIV protease inhibitors, fusion inhibitors, and CCR-5 inhibitors.

21. A method of Claim 20, wherein the reverse transcriptase inhibitor is selected from the group AZT, ddC, ddI, d4T, 3TC, delavirdine, efavirenz, nevirapine, trovirdine, MKC-442, HBY 097, HBY1293, GW867, ACT, UC-781, UC-782, RD4-2025, MEN 10979, AG1549 (S1153), TMC-120, TMC-125, Calanolide A, and PMPA, and the protease inhibitor is selected from the group saquinavir, ritonavir, indinavir, amprenavir, nelfinavir, palinavir, BMS-232623, GS3333, KNI-413, KNI-272, LG-71350, CGP-61755, PD 173606, PD 177298, PD 178390, PD 178392, U-140690, ABT-378, DMP-450, AG-1776, VX-175, MK-944, and VX-478, the CCR-5 inhibitor is selected from TAK-779 (Takeda), SC-351125 (SCH-C, Schering) and SCH-D (Schering), and the fusion inhibitor is selected from T-20 and T1249.

22. A method of Claim 21, wherein the reverse transcriptase inhibitor is selected from the group AZT, efavirenz, and 3TC and the protease inhibitor is selected from the group saquinavir, ritonavir, nelfinavir, and indinavir.

23. A method of Claim 22, wherein the reverse transcriptase inhibitor is AZT.

24. A method of Claim 23, wherein the protease inhibitor is indinavir.

25. A pharmaceutical kit useful for the treatment of HIV infection, which comprises a therapeutically effective amount of:

(a) a compound according to one of Claim 1; and,

(b) at least one compound selected from the group consisting of HIV reverse transcriptase inhibitors and HIV protease inhibitors, in one or more sterile containers.